Second patent filed for novel orexin 1 antagonist programme

A second patent application for novel orexin 1 antagonists has been filed on 25 October 2017. This is an entirely new composition of matter patent supporting our binge eating disorder and alcohol [...]

Chronos Senior Mangement interviewed at The Telegraph studios

Chronos CEO, CSO and VP Corporate Development were interviewed at The Telegraph studios recently. Click here to see the interview on our approach to degenerative and behavioural brain disease.

Patent granted in Malaysia for treatment of age-related disorders

Patent filed for novel orexin 1 antagonist programme

A patent application for our novel orexin 1 antagonist has been filed on 1 September 2017. This is an entirely new composition of matter patent supporting our binge eating disorder and alcohol [...]

Positive cell culture data for RDC5 in ALS

Chronos CEO and VP Corporate Development interviewed by European CEO magazine

See the interview here.

Chronos CEO wins European CEO, Best CEO in the Drug Discovery Industry

Chronos CEO, Dr Huw Jones has been awarded best CEO in the European drug discovery industry by online and print magazine European CEO. Read the press release.    

Dr Timothy Schulz-Utermoehl to join as VP Pre-Clinical Development

Dr Schulz-Utermoehl has over 17 years’ experience in the pharmaceutical industry, spanning early and late-stage discovery research and pre-clinical development. He and Dr Fraser Murray will be [...]

Dr Fraser Murray joins as VP Pre-Clinical Development

Dr Murray brings more than 20 years’ of drug discovery and early development experience across a range of therapeutic areas, including neurodegeneration, psychiatry, inflammation and [...]

Shire becomes a strategic equity investor in Chronos